Clarivate Highlights 13 Potential Drugs to Watch in Latest Report

Published on: 

Clarivate's Drugs to Watch report highlights 13 potential blockbuster drugs and gamechangers set to launch in 2024.

Clarivate, a global information services provider, has announced, in a Jan. 8, 2024 press release, the publication of its annual Drugs to Watch report, highlighting 13 potential blockbuster drugs and gamechangers that will launch in 2024.

Now in its eleventh year, the Drugs to Watch report provides predictive analysis of drugs set to launch with the potential to be highly commercially and/or clinically successful. In the latest edition, Clarivate analysts have identified 13 new-to-market therapeutics and drugs as potential blockbusters—drugs that are likely to achieve $1 billion in annual sales—or game-changers in terms of benefits for patients.

The drugs highlighted in the report cover a wide therapeutic base ranging from treatments for breast cancer, hemophilia A, sickle cell disease, Crohn’s disease, ulcerative colitis, respiratory syncytial virus, and multiple myeloma, among others. Additionally, the 2024 report sheds light on the growing chronic disease market in Mainland China, with the analysts picking out seven drugs that they predict as being likely to achieve blockbuster status by 2029 or as having a significant impact for Chinese patients in need of better treatment options.


“The fundamentals underpinning the biopharma sector have never been stronger, with new technologies fueling medical advancements and providing treatment options to patients with previously unmet needs,” said Mike Ward, global head of Thought Leadership, Life Sciences and Healthcare, Clarivate, in the press release. “Leveraging deep industry expertise and comprehensive therapeutic area differentiated data, this year’s Drugs to Watch report identifies innovative medicines based on recent scientific breakthroughs poised to have extraordinary impacts on patient outcomes.”

The full report is available for download from Clarivate’s website, and more details will be provided in the Editor’s Comment for Pharmaceutical Technology Europe’s January edition.

Source: Clarivate